Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV. Herling CD, et al. Among authors: bondaruk je. Lancet Oncol. 2019 Nov;20(11):1576-1586. doi: 10.1016/S1470-2045(19)30503-0. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31582354 Free PMC article. Clinical Trial.
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Blehm KN, et al. Among authors: bondaruk je. Clin Cancer Res. 2006 Aug 1;12(15):4671-7. doi: 10.1158/1078-0432.CCR-06-0407. Clin Cancer Res. 2006. PMID: 16899617 Free article.